Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer (TNBC) is a heterogeneous disease that carries the poorest prognosis of all breast cancers. Although novel TNBC therapies in development are frequently targeted toward tumors carrying a specific genomic, transcriptomic, or protein biomarker, it is poorly understood how these biomarkers are correlated.
No takes yet. Share an insight, caveat, or question.
Jovanović et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: